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Introduction
Guidelines published by the Global Initiative for
Asthma indicate that asthma control can and should
be achieved and maintained in most patients by
employing appropriate pharmacotherapy and mini-
mising environmental stimuli (1,2). However, this
goal is not always met and the majority of patients
still remain uncontrolled. In a recent survey of over
2000 adults diagnosed with asthma in ﬁve European
countries only 38% of treated patients were well con-
trolled, and in Germany this ﬁgure was lower, at 26%
(3). Currently, initial treatment generally consists of a
ﬁxed low dose of an inhaled corticosteroid (ICS)
(200–500 lg beclomethasone dipropionate equiva-
lent) with a short-acting b2-agonist (SABA) for
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SUMMARY
Aims: This retrospective, observational cohort study aimed to compare treatment
outcomes and healthcare costs in the year after initiation of maintenance treat-
ment with budesonide⁄formoterol or salmeterol⁄ﬂuticasone in a German health-
care setting. Methods: Data on German asthma patients initiating treatment with
budesonide⁄formoterol or salmeterol⁄ﬂuticasone between June 2001 and June
2005 were obtained from the IMS Disease Analyzer database. The primary out-
come was the probability of treatment success, deﬁned according to short-acting
b2-agonist prescriptions and switches or addition of controller medications, during
the postindex year. A secondary deﬁnition of treatment success included hospitali-
sations and oral corticosteroid (OCS) prescriptions. Secondary outcomes included
severe asthma exacerbations, deﬁned as ‡1 OCS prescription, asthma-related hos-
pitalisation and⁄or referral. The effect of treatment on costs was estimated using
generalised linear models, adjusting for patient and physician characteristics.
Results: There were no signiﬁcant differences between the budesonide⁄formoterol
(n = 1456) and salmeterol⁄ﬂuticasone (n = 982) groups in disease severity mark-
ers in the pre-index year. Patients on budesonide⁄formoterol had a 44% greater
probability of treatment success [odds ratio (OR): 1.44; p = 0.0003] according to
the primary deﬁnition and a 26% greater probability (OR: 1.26; p = 0.0119)
according to the secondary deﬁnition, fewer severe exacerbations ()33.4%;
p = 0.0123) and fewer OCS prescriptions ()31.5%; p = 0.0082) compared with
salmeterol⁄ﬂuticasone, after controlling for baseline characteristics. Adjusting for
covariates, budesonide⁄formoterol had a signiﬁcant inverse relationship on
asthma-related costs compared with salmeterol⁄ﬂuticasone ()13.4%; p < 0.001).
Total cost (asthma- and non-asthma-related costs) was 12.6% lower for budeso-
nide⁄formoterol (p < 0.0001). Conclusion: This study suggests that for patients
with chronic asthma in Germany, budesonide⁄formoterol rather than salmeter-
ol⁄ﬂuticasone had a higher likelihood of treatment success, and that budeso-
nide⁄formoterol is the less costly option. Although the cohorts appeared to be
well matched at baseline, the results should be interpreted with caution given the
observational nature of the study.
What’s known
d Clinical studies have shown that, for patients
with asthma uncontrolled by low-dose inhaled
corticosteroids (ICS), maintenance treatment with
ﬁxed-dose combinations of an ICS and a long-
acting b2-agonist (LABA) are effective in
achieving asthma control and preventing
exacerbations.
d Retrospective database studies have shown that
combination products may increase compliance
and treatment outcomes compared with
separately administered ICS and LABA.
d Recent meta-analyses have indicated that the
two most commonly used ﬁxed-dose ICS ⁄ LABA
combinations (budesonide ⁄formoterol and
salmeterol ⁄ﬂuticasone) may not have the same
level of efﬁcacy with regard to asthma-related
hospitalisations ⁄emergency room visits, the risk
being greater with salmeterol ⁄ ﬂuticasone.
What new
d This database analysis of ﬁxed-dose ICS ⁄ LABA
combinations adds to a growing body of
evidence suggesting that there may be efﬁcacy
differences between budesonide ⁄ formoterol and
salmeterol ⁄ﬂuticasone. The results suggest that,
in a real-life German healthcare setting:
d Patients initiating treatment with budesonide ⁄
formoterol had an increased chance of
treatment success and reduced exacerbations
compared with salmeterol ⁄ ﬂuticasone.
d Fixed-dose budesonide ⁄ formoterol is less
costly than salmeterol ⁄ﬂuticasone for the
treatment of chronic asthma.
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demonstrated that, in patients in whom asthma is not
controlled with low-dose ICS, the combination of an
ICS and a long-acting b2-agonist (LABA) improves
asthma control more effectively than higher doses of
ICS alone (4–7). This combination is now the recom-
mended maintenance therapy for patients stepping up
from low-dose ICS (1,2). Fixed-dose combination
inhalers have been developed, which offer improved
convenience over ICS and LABA administered in
separate devices and ensure better long-term compli-
ance to anti-inﬂammatory therapy (8). Two previous
database studies indicated that combination products
improve both compliance and treatment outcomes
compared with the concurrent administration of
individual products via separate inhalers (9,10).
The two most commonly used ﬁxed combination
products, budesonide⁄formoterol (Symbicort
 ,
AstraZeneca, Lund, Sweden) and salmeterol⁄ﬂutica-
sone (Seretide , GlaxoSmithKline, Uxbridge, UK or
Viani , GlaxoSmithKline), have both been shown to
be highly effective in patients with persistent asthma
that is uncontrolled with ICS alone (6,11–15).
Randomised controlled studies in moderate-to-severe
asthma have shown similar daily or weekly control
and overall exacerbation rates for both combinations
when used as ﬁxed-dose maintenance therapy (16–
18). Nevertheless, in the study by Kuna and col-
leagues and a recent meta-analysis of three clinical
trials, including over 4000 patients, it was found that
the risk or rate of exacerbations requiring hospitali-
sations⁄emergency treatments was lower with sus-
tained ﬁxed-dose budesonide⁄formoterol than with
sustained ﬁxed-dose salmeterol⁄ﬂuticasone (18–20).
This important efﬁcacy difference was consistent in
all three of the individual studies included in the
analysis. Two recent meta-analyses also indicate that
these two combinations may have different effects on
asthma-related hospitalisations. In an analysis assess-
ing the safety of formoterol administered in combi-
nation with an ICS in 18 double-blind clinical
studies, fewer asthma-related hospitalisations and
asthma-related serious adverse events were observed
in the formoterol⁄ICS group compared with the
ICS-alone control group (21). These results were
independent of the ICS dose in the control group. In
contrast, an analysis of 52 clinical studies of salme-
terol showed no difference in asthma-related hospi-
talisations when salmeterol was added to an ICS
compared with ICS alone (22). Thus, it appears that
combination therapies may not have the same level
of efﬁcacy across all outcome measures important in
asthma management.
It is not certain if the reduced risk of requiring
hospitalisation⁄emergency treatment with budeso-
nide⁄formoterol compared with salmeterol⁄ﬂutica-
sone in meta-analyses of randomised controlled trials
is likely to be seen in the normal clinical setting. In
this case, database studies can provide valuable infor-
mation on how these commonly used combination
therapies affect cost-driving outcomes, such as exac-
erbations, in everyday practice. Such analyses are also
important for establishing the overall relative
cost-effectiveness of initiating treatment with combi-
nations of budesonide⁄formoterol or salmeterol⁄
ﬂuticasone in asthma patients. The relative effective-
ness and cost-effectiveness of initiating maintenance
therapy with budesonide⁄formoterol and salmeter-
ol⁄ﬂuticasone under standard clinical conditions in
Germany is not known. The aim of this retrospective
database cohort study was to compare treatment
outcomes and healthcare costs in the year after
the initiation of maintenance treatment with
budesonide⁄formoterol or salmeterol⁄ﬂuticasone in a
German healthcare setting.
Methods
Sources of data
This study was a retrospective database cohort study
carried out using data obtained from the IMS Dis-
ease Analyzer database (http://www.imshealth.com).
This is a database that captures real-life, longitudinal,
anonymised data on patients and prescribers across
Europe. In Germany, approximately 2000 physicians
record data on 10 million patients. The data
recorded include patient demographics, physician
characteristics, prescriptions, hospital admissions and
specialist referrals.
Patient population
The cohorts identiﬁed for the study included patients
who initiated maintenance treatment with budeso-
nide⁄formoterol or salmeterol⁄ﬂuticasone between
June 2001 and June 2005. Budesonide⁄formoterol is
reported to be effective when used as both mainte-
nance and reliever therapy compared with traditional
ICS⁄LABA combinations plus SABA (18,23,24).
However, during the time period when the data used
in this study was recorded, budesonide⁄formoterol
was approved for use as maintenance treatment only.
In this study, the index date was deﬁned as the date
of their ﬁrst prescription of ICS⁄LABA combination.
Eligible patients were over 12 years of age, had a
diagnosis of asthma (ICD-10 codes J45–46) and con-
tinuous enrolment in the database from 12 months
prior to the index date to 12 months after the index
date (IMS data was collected between June 2000 and
June 2006). Patients with diagnosed chronic obstruc-
tive pulmonary disease or use of ICS⁄LABA prior to
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(June 2001) were excluded.
Treatment outcomes
The predeﬁned primary end-point was the probabil-
ity of full treatment success vs. partial or no treat-
ment success over 12 months following ﬁrst
prescription of an ICS⁄LABA combination therapy.
Treatment success was deﬁned a priori according to
primary or secondary criteria as described in Table 1.
All events were assumed to be asthma related if a
code for asthma diagnosis (ICD-10 codes J45–J46)
was recorded on the same date. In case there was no
link to diagnosis for an event, an algorithm was used
to deﬁne whether an event was related to asthma.
Hospitalisations, referrals and oral corticosteroid
(OCS) prescriptions were assumed to be related to
asthma if they occurred within the 7 days before or
after an event with a recorded diagnosis of asthma.
Referrals associated with asthma were deﬁned as all
referrals to either a pneumologist or an allergologist.
Secondary outcomes included asthma exacerba-
tions, SABA use, overall OCS prescriptions and
asthma-related referrals and hospitalisations⁄emer-
gency room visits. Asthma exacerbations were deﬁned
as any event (prescription, hospitalisation, sick note or
referral) with a diagnosis of acute severe asthma status
(ICD-10 code J46) or any asthma-related OCS
prescription occurring within the 7 days before or the
7 days after an event with recorded diagnosis of
asthma or acute lower respiratory tract infection
(ICS-10 codes J45, J46, J22), or any referral or hospi-
talisation occurring within 7 days before or after an
event with recorded diagnosis of asthma or acute
lower respiratory tract infections. In cases where two
or more acute exacerbations occurred within 7 days, it
was counted as only one episode. The proportion
of patients that did not renew their initial
prescription was investigated as a measure of dis-
continuations.
Cost analysis
The health economic evaluation was conducted from
a third-party payer perspective and compared costs
related to each therapy in terms of medications and
other asthma-related healthcare resource use. Unit
costs for asthma medications were estimated from
producer sales prices using a program provided by
IMS. For budesonide⁄formoterol and salmeterol⁄ﬂu-
ticasone, 2007⁄2008 prices were obtained from the
Rote Liste (http://www.rote-liste.de). Costs for physi-
cian consultations and outpatient procedures were
obtained from the Einheitbewertungsmaßstab sched-
ules and costs for hospitalisations came from the
German reﬁned diagnosis-related groups (http://
www.g-drg.de/) (Table 2).
Table 1 Deﬁnition of treatment success in the year following initiation of budesonide⁄formoterol or
salmeterol⁄ﬂuticasone therapy, according to primary and secondary criteria
Category Primary success criteria Secondary success criteria
Full success Average SABA consumption of < 0.5 doses* per day
and
No addition of asthma medication (leukotriene antagonist,
theophylline, omalizumab, fenoterol + ipratropium
combination) between 10 and 52 weeks after
index date or any switch to alternative ICS⁄LABA
ﬁxed combination or ICS + LABA
As for the primary deﬁnition
and
No asthma-related OCS prescription
and
No asthma-related referrals or
hospitalisations
Partial success An otherwise successfully treated patient who has an
average SABA consumption between 0.51–2
doses per day
As for the primary deﬁnition
and⁄or
1–2 OCS prescriptions
and
No asthma-related referrals or
hospitalisation
No success Average SABA consumption of more than two doses⁄day
or
Addition of asthma medication between 10 and 52 weeks
after index date or switch to alternative ICS⁄LABA ﬁxed
combination or ICS + LABA
As for the primary deﬁnition
and⁄or
> Two OCS prescriptions
and⁄or
At least one asthma-related referral or
hospitalisation
*Expressed in dry powder inhaler equivalents. ICS, inhaled corticosteroid; LABA, long-acting b2-agonist; OCS, oral corticosteroid; SABA,
short-acting b2-agonist.
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Logistic regression was used to estimate the associa-
tion between treatment group and treatment success,
adjusting for patient characteristics. Treatment suc-
cess was modelled as a dichotomic variable, grouping
the categories ‘partial success’ and ‘no success’
together. Potential covariates included disease sever-
ity according to treatment history, age and insurance
status, and centre characteristics according to the
physician and the specialty of the lead physician.
Covariates that were not statistically signiﬁcant at the
5% level were removed. Renewal rates of ICS⁄LABA
prescriptions were assessed as a measure of treatment
persistence. Generalised linear models were used to
estimate the effect of treatment on severe exacerba-
tions, resource use and costs, adjusting for patient
and physician characteristics. The choice of statistical
distribution was based on goodness-of-ﬁt statistics,
which lead to the application of lognormal and
gamma distributions, depending on the type of
resource or cost modelled.
Results
Patients
Among the 2438 patients who met the study inclu-
sion criteria, 1456 were treated with budesonide⁄
formoterol (administered via Turbuhaler) and 982
were treated with salmeterol⁄ﬂuticasone (adminis-
tered via Diskus in the majority of patients). These
patients represented 7.1% and 4.8% of the database
respectively (Figure 1). The majority of exclusions
were due to patients not fulﬁlling 24 months of fol-
low-up or having no history of asthma. Patient char-
acteristics are summarised in Table 3. The mean age
was approximately 48 years in both groups and there
were no signiﬁcant differences between groups in
markers of disease severity in the pre-index year,
based on prescriptions of asthma medication, refer-
rals (p = 0.2829) or hospitalisations (p = 0.7764).
SABA prescriptions in the pre-index year were
recorded in 41.2% and 39.8% of patients in the
salmeterol⁄ﬂuticasone and budesonide⁄formoterol
groups, respectively, at an average of approximately
1.8 inhalations per day [dry power inhaler (DPI)
equivalent]. There was no statistically signiﬁcant
difference in reported comorbidities between groups
(rhinitis, p = 0.0867 and gastro-oesophageal reﬂux
disease, p = 0.9764).
In both groups, the majority of patients were fol-
lowed at a general practitioner (GP)-lead clinic and
the minority were followed at a specialist-lead prac-
tice. However, comparison of the two groups showed
a higher proportion of patients at GP-lead clinics in
Table 2 Unit costs
Type of cost Unit Cost, €
Physician
Patient age 12–59 years Routine visit 6.75*
Asthma-related visit 29.50*
> 60 years Routine visit 10.75*
Asthma-related visit 33.50*
Allergologist Referral 87.75*
Pneumologist Referral 57.20*
Hospitalisation associated with asthma Hospital stay 1607.35
G-DRG associated with asthma diagnosis
Bronchitis and bronchial asthma, > 55 years old
or with heavy complications (1619 cases)
Hospital stay (6.8 days) 2012.50§
Bronchitis and bronchial asthma, age
6–59 years old and without heavy
complication (2118 cases)
Hospital stay (4.0 days) 1378.46§
Diseases⁄disturbances of respiratory organs,
with artiﬁcial respiration > 24 h, without
complication (6 cases)
Hospital stay (10.2 days) 5651.31§
*Unit costs obtained from EBM schedules, assuming a unit cost of €0.05 for each EBM point. It was assumed that two spirographies
and one body plethysmography were conducted for all referrals. An estimated average cost calculated from the three G-DRG associ-
ated with a possible main diagnosis of asthma or acute exacerbation. This weighted average cost was calculated based on the number
of cases associated with one asthma diagnosis and a co-payment of €10 per hospital day was applied. §Unit costs obtained from
G-DRG (http://www.g-drg.de/). G-DRG, German reﬁned diagnosis-related groups; EBM, Einheitbewertungsmaßstab.
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portion of patients followed by specialists in the
salmeterol⁄ﬂuticasone group. These differences
resulted in a statistically signiﬁcant association
between treatment group and type of practice
(p = 0.0022). Insurance status also differed signiﬁcantly
Figure 1 Selection of patients from the IMS Disease Analyzer database
Table 3 Characteristics of patients initiating treatment with budesonide⁄formoterol or salmeterol⁄ﬂuticasone
Characteristic
SAL⁄FLU
group (n = 982)
BUD⁄FORM group
(n = 1456) p-value
Females, % 55.0 57.2 0.278
Mean age, years 47.6 48.4 0.32
Insurance status, %
Common medical insurance plan 28.1 28.9
0.0008
Other 11.2 11.3
Company health insurance fund 16.8 20.1
Substitute sickness insurance society 29.5 30.7
Private health insurance 14.4 9.0
Lead physician, %
General practice 72.0 76.2
0.0022 Internal medicine 20.9 19.8
Specialist (other) 7.1 4.1
Comorbidities, %
Rhinitis 15.6 13.1 0.0867
Gastro-oesophageal reﬂux disease 3.9 3.9 0.9764
Events in pre-index year, %
At least one referral related to asthma 10.6 9.3 0.2829
At least one hospitalisation related to asthma 0.7 0.6 0.7764
Prescriptions in pre-index year*, %
SABA 41.2 39.8 0.4663
ICS 28.2 26.0 0.2344
OCS 8.6 6.5 0.0596
LABA 13.5 13.9 0.8165
ICS + LABA non-ﬁxed combination 10.1 8.2 0.1053
*Proportion of patients with at least one prescription. This reﬂects the lowest possible proportion as patients could have received pre-
scriptions at another practice not reporting to the IMS Disease Analyzer. Note, because of rounding percentages, these may not always
add up to 100%. p-values for association with type of practice and insurance are based on independence chi-square tests. All others
are t-tests. BUD⁄FORM, budesonide⁄formoterol; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist; OCS, oral corticosteroid;
SABA, short-acting b2-agonist; SAL⁄FLU, salmeterol⁄ﬂuticasone.
g
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patients in the budesonide⁄formoterol group had a
company health insurance fund, while more patients
in the salmeterol⁄ﬂuticasone group had private
insurance.
Treatment success
A higher proportion of patients in the budeso-
nide⁄formoterol cohort met the criteria for primary
and secondary treatment success compared with the
salmeterol⁄ﬂuticasone cohort (unadjusted analysis;
Figure 2). As expected, the proportion of successfully
treated patients for both budesonide⁄formoterol and
salmeterol⁄ﬂuticasone was lower when applying the
secondary deﬁnition, which included OCS use and
referrals (Figure 2). For both deﬁnitions of treatment
success, a larger proportion of patients in the salme-
terol⁄ﬂuticasone group, compared with the budeso-
nide⁄formoterol group, failed to meet each of the
subcriteria for full success (37.5% vs. 31.7%, Table 4).
The most common reasons for treatment failure in
both groups were addition of another asthma medi-
cation, SABA use at > 0.5 doses⁄day (DPI equiva-
lent) and two or more asthma-related referrals
(Table 4).
In the logistic regression model adjusted for dis-
ease severity and pre-index SABA use, the odds for
achieving the primary deﬁnition of ‘full success’ vs.
‘partial or no success’ increased by 44% with budeso-
nide⁄formoterol [odds ratio (OR): 1.44; p = 0.0003,
Figure 3]. Patients treated with budesonide⁄formo-
terol also had a greater probability of treatment
A
B
Figure 2 Proportions of salmeterol⁄ﬂuticasone- (white bars) or budesonide⁄formoterol- (black bars) treated patients
meeting the criteria for primary (A) or secondary (B) treatment success. p-values calculated via chi-squared test of
independence between treatment success and treatment group, for primary success, p = 0.0060 and for secondary success,
p = 0.0928
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1.26; p = 0.0119).
Subgroup analyses were conducted according to
prescription renewal of ICS⁄LABA combination
treatment. The logistic regression model for the
primary deﬁnition of treatment success showed a
signiﬁcant treatment effect with budesonide⁄formo-
terol for the subgroup of the 1169 patients who
did not renew their initial prescription (OR: 1.422;
p = 0.0333) and for the 1269 patients with at least
two prescriptions (OR: 1.426; p = 0.0064). For the
586 patients with a prescription renewal
within 4 months of index date the OR was 1.214,
which did not reach statistical signiﬁcance
(p = 0.3011).
Other treatment outcomes
A signiﬁcantly higher number of severe exacerbations
was observed among patients treated with salmeter-
ol⁄ﬂuticasone compared with budesonide⁄formoterol
in the unadjusted analysis (0.1955 vs. 0.103 episodes
per patient per year; p = 0.0018; Table 5). Linear
regression analysis (adjusted for pre-index ICS, LABA
and SABA use, gender and numbers of exacerbations,
OCS prescriptions, referrals and hospitalisations over
the pre-index period) indicated that budesonide⁄for-
moterol reduced the number of severe exacerbations
by 33.4% compared with salmeterol⁄ﬂuticasone
(p = 0.0123). There was no statistically signiﬁcant
Table 4 Reasons for failure to meet primary or secondary criteria for treatment success
Reason (% of all patients)
SAL⁄FLU
group (n = 982)
BUD⁄FORM
group (n = 1456)
SABA use
> 0.5 to £ 2 doses⁄day 15.7 15.2
> 2 doses⁄day 8.8 7.8
Addition of other asthma medication* between week 10 and
week 52 after index date
25.4 20.2
Switch from ICS + LABA combination to another 7.0 3.6
OCS prescriptions
1–2 prescription 5.2 3.8
> 2 prescriptions 2.0 0.9
Referrals related to asthma
1 referral 5.7 3.9
> 2 referrals 9.9 9.0
Hospitalisation related to asthma
1 hospitalisation 1.1 0.3
> 2 hospitalisations 0.2 0.2
*Leukotriene antagonist, IgE (omalizumab), anticholinergic (ipratropium, ipratropium + fenoterol combination), theophylline, combina-
tion cromolyn⁄reproterol. Not more than 11% of failures in either group were associated with any one medication. BUD⁄FORM,
budesonide⁄formoterol; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist; OCS, oral corticosteroid; SABA, short-acting
b2-agonist; SAL⁄FLU, salmeterol⁄ﬂuticasone.
Figure 3 Relative probability of full treatment success.
Values to the right of the vertical line indicate a higher
probability of full treatment success with
budesonide⁄formoterol compared with
salmeterol⁄ﬂuticasone. The ﬁlled circles represent the
point estimate for the odds ratios (OR) and the
horizontal lines the range of the conﬁdence intervals. The
regression models used to derive the adjusted OR included
pre-index inhaled corticosteroid (ICS), long-acting b2-
agonist (LABA) and short-acting b2-agonist (SABA) use
for the primary deﬁnition and pre-index ICS, LABA
and SABA use, age and physician speciality for the
secondary deﬁnition
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referrals or hospitalisations between the budeso-
nide⁄formoterol and the salmeterol⁄ﬂuticasone
groups and mean SABA use did not differ between
groups in the postindex year. However, overall OCS
prescriptions were more frequent in the salmeter-
ol⁄ﬂuticasone-treated patients compared with the
budesonide⁄formoterol-treated patients. Almost half
of the patients in both the salmeterol⁄ﬂuticasone and
the budesonide⁄formoterol groups (45% and 49.4%
respectively) did not renew the prescription of their
initial ICS⁄LABA combination.
Costs
Total mean asthma-related costs were signiﬁcantly
greater for the salmeterol⁄ﬂuticasone group com-
pared with the budesonide⁄formoterol group
(Figure 4). The biggest differences were seen for
asthma-related medications and asthma-related visits,
for which costs were signiﬁcantly greater for the
salmeterol⁄ﬂuticasone group than the budeso-
nide⁄formoterol group. Mean costs associated with
asthma-related referrals and hospitalisations were not
signiﬁcantly different between treatment groups.
A generalised linear model using a log-normal dis-
tribution was used to estimate the effect of treatment
on costs. When adjusting for covariates, budeso-
nide⁄formoterol reduced total asthma-related costs
()13.4%: p < 0.001) compared with salmeterol⁄
ﬂuticasone. Total cost, including both asthma-related
(medication, visits, referrals and hospitalisations) and
non-asthma-related (medications and visits) costs,
was 17.1% lower for budesonide⁄formoterol com-
pared with salmeterol⁄ﬂuticasone in the crude com-
parison (683.57€ vs. 824.67€; p = 0.0001) and 12.6%
lower in the adjusted analysis (p < 0.0001).
Discussion
Clinical studies have shown that for patients with
asthma uncontrolled by low-dose ICS treatment,
ﬁxed-dose combinations of an ICS and a LABA are
Table 5 Secondary treatment outcomes in the post-index year
Outcomes
SAL⁄FLU
group
(n = 982)
BUD⁄FORM
group
(n = 1456)
Relative difference
(BUD⁄FORM vs. SAL⁄FLU)
p-value* Crude (%) Adjusted* (%)
Asthma exacerbations (mean episodes⁄patient) 0.20 0.10 )47.3 )33.4 0.0123
SABA use (mean number of doses⁄patient⁄day) 0.60 0.52 )13.7 )8.7 0.2297
OCS (mean prescriptions⁄patient) 0.30 0.17 )47.3 )31.5 0.0082
Asthma-related referrals (mean number⁄patient) 0.19 0.18 )9.5 )9.5 0.4358
Asthma-related hospitalisations (mean number⁄patient) 0.021 0.012 )45.4 )2.9 0.7228
*Adjusted for pre-index inhaled corticosteroid, long-acting b2-agonist and short-acting b2-agonist (SABA) use, gender and numbers of
exacerbations, oral corticosteroid (OCS) prescriptions, referrals and hospitalisations over the pre-index period. BUD⁄FORM, budeso-
nide⁄formoterol; SAL⁄FLU, salmeterol⁄ﬂuticasone.
Figure 4 Crude comparison of costs in the postindex year between salmeterol⁄ﬂuticasone- (white bars) and budesonide⁄
formoterol- (black bars) treated patients. p-values were derived using an unequal variance t-test
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administered ICS and LABA (8–10). This database
analysis of ﬁxed-dose ICS⁄LABA combinations adds
to a growing body of evidence suggesting that there
may be efﬁcacy differences between budesonide⁄for-
moterol and salmeterol⁄ﬂuticasone across certain
cost-driving outcomes. The results suggest that, in a
German healthcare setting, better outcomes can be
achieved at a lower overall cost if patients are treated
with budesonide⁄formoterol instead of salmeterol⁄
ﬂuticasone.
The economic cost of asthma is considerable both
in terms of direct medical costs (such as hospital
admissions and cost of pharmaceuticals) and indirect
costs (such as time lost from work and premature
death). Ineffective management of asthma can
increase these costs, and the overall cost-effectiveness
of new therapies is an important consideration. Eco-
nomic analyses in Sweden have shown that combin-
ing budesonide and formoterol in one device may be
cost-effective compared with the two agents adminis-
tered separately (25,26). This study is the ﬁrst of its
kind to compare the cost-effectiveness of budeso-
nide⁄formoterol and salmeterol⁄ﬂuticasone using a
German database analysis. The analysis indicates that,
relative to the use of salmeterol⁄ﬂuticasone, budeso-
nide⁄formoterol treatment is less costly and is associ-
ated with a greater rate of treatment success in the
German healthcare setting. The difference in cost
appeared to be driven by fewer physician visits and
lower expenditure on medications in the treatment
practices where budesonide⁄formoterol was com-
monly used than in the practices where salmeter-
ol⁄ﬂuticasone was used. In database surveys, both
the clinician and the treatment are likely to inﬂuence
outcomes. Of note, in this analysis there were some
differences between the two treatment groups in
terms of lead physician type and insurance status. A
higher proportion of patients in the budesonide⁄for-
moterol group were followed at a GP-lead clinic,
while a higher proportion of the salmeterol⁄ﬂutica-
sone group were followed at a specialist-lead clinic.
Although statistically signiﬁcant, these differences
were small and have been controlled for through the
use of regression analyses.
The fact that a high proportion of patients did not
continue treatment with ICS⁄LABA for the whole
study period, particularly in the budesonide⁄formo-
terol group, commands caution in interpreting the
results. However, the effect of budesonide⁄formoterol
on treatment success in the subgroup of patients
who did not renew their initial prescription (OR:
1.422; p = 0.0333) was similar to the effect estimated
in the whole sample, using logistic regression.
Among patients with at least one prescription
renewal within 4 months of the index date, the prob-
ability of treatment success was also higher for those
treated with budesonide⁄formoterol, although the
corresponding effect was not statistically signiﬁcant.
The ICS⁄LABA prescription renewal rates observed
in this analysis are similar to those reported in a
pharmacy database study investigating salmeter-
ol⁄ﬂuticasone adherence and persistence in 5504
patients in the USA (27). More than half the patients
ﬁlled a 30-day prescription only once over a 1-year
interval, suggesting that adherence to ICS⁄LABA
combinations may be considerably lower than those
reported in clinical trials. Evidence also indicates
that, in ‘real-life’, adherence to asthma therapy is
greater among patients using ﬁxed-dose combination
inhalers compared with those prescribed separate ICS
and LABA inhalers (8).
As with all database studies there are several other
limitations not usually encountered in controlled
clinical trials that must be considered. Lack of fol-
low-up between practices and the absence of any
record of medications prescribed by specialists could
lead to underestimation of prescriptions. However,
this is unlikely to account for the differences
observed between treatment groups in this compara-
tive study as pre-index referrals and asthma-related
prescriptions were similar between the two groups.
Missing diagnoses and the use of algorithms to iden-
tify asthma-related events may also affect the results;
however, this is also unlikely to have resulted in any
signiﬁcant bias in this study because proportions of
missing diagnoses between treatment groups were
similar. Of note, the probability of success was signif-
icantly higher in the budesonide⁄formoterol group in
analyses using other variants of the deﬁnition of
treatment success, taking into account events not
related to asthma (results not reported). Further-
more, costs were lower in the budesonide⁄formoterol
group regardless of whether costs unrelated to
asthma, including costs for other medications and
non-asthma-related physician visits, were included or
not.
Two key objectives listed in guidelines for the suc-
cessful management of chronic asthma are to achieve
and maintain control of symptoms and to reduce or
prevent asthma exacerbations. The results of this
study suggest that in the German healthcare setting
these goals are achieved more often in patients
prescribed budesonide⁄formoterol than in patients
prescribed salmeterol⁄ﬂuticasone, and that budeso-
nide⁄formoterol appears to represent a more
cost-effective option based on the available evidence.
Although the cohorts appeared to be well matched at
baseline, the results should be interpreted with
caution given the observational nature of the study.
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